Pharmacological developments obtained from marine natural products and current pipeline perspective

Natural Product Communications

Volumn 6, Issue 2, 2011, Pages 287-300

  Elkin Galeano, J ^a   Rojas, Jhon J ^a   Martínez, Alejandro ^a  

^a UNIVERSIDAD DE ANTIOQUIA   (Colombia)

Author keywords

Action mechanism; Drugs; Marine natural products; Pharmacology

Indexed keywords

ANTIINFLAMMATORY AGENT; AVE 0547; BRYOSTATIN 1; CARBOPLATIN; CEMADOTIN; CISPLATIN; CONTIGNASTEROL; CYTARABINE; DEHYDRODIDEMNIN B; DIDEMNIN B; DOLASTATIN; DOLASTATIN 10; DOLASTATIN 15; ELISIDEPSIN; ER 076349; ERIBULIN; ERLOTINIB; FLUOROURACIL; GEMCITABINE; HALICHONDRIN B; IPL 512602; IPL 576092; KAHALALIDE F; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; NATURAL PRODUCT; NSC 707390; OMEGA CONOTOXIN MVIIA; SOBLIDOTIN; TASIDOTIN; TRABECTEDIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIDARABINE; VINCRISTINE; BIOLOGICAL PRODUCT;

AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ASTHENIA; ASTHMA; ATAXIA; BIODIVERSITY; BLEEDING; BREAST CANCER; CELL CYCLE S PHASE; COLORECTAL CARCINOMA; CONFUSION; CONTINUOUS INFUSION; CONUS GEOGRAPHUS; CONUS MAGNUS; CREATINE KINASE BLOOD LEVEL; CRYSTALLIZATION; CYTOTOXICITY; DEPRESSION; DIARRHEA; DIZZINESS; DOLABELLA AURICULARIA; DROWSINESS; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DYSGEUSIA; DYSKINESIA; ECTEINASCIDIA TURBINATA; EMOTIONAL STRESS; EUNICELLA CAVOLINI; EYE PAIN; FATIGUE; FLU LIKE SYNDROME; HUMAN; HYPOGLYCEMIA; HYPOKALEMIA; KERATITIS; KERATOCONJUNCTIVITIS; KIDNEY CANCER; KIDNEY CARCINOMA; LIVER TOXICITY; LUNG CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; MARINE SPECIES; MELANOMA; MEMORY DISORDER; MOUTH ULCER; MUSCLE SORENESS; MYALGIA; NAUSEA; NEUROPATHIC PAIN; NEUROPATHY; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; PAIN; PETROSIA; PETROSIA CONTIGNATA; PHLEBITIS; PHOTOPHOBIA; PHYSICAL CHEMISTRY; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; RECOMMENDED DRUG DOSE; REVIEW; SEDATION; SIDE EFFECT; SOFT TISSUE SARCOMA; THIN LAYER CHROMATOGRAPHY; TRIDIDEMNUM SOLIDUM; URIC ACID BLOOD LEVEL; VOMITING; X RAY CRYSTALLOGRAPHY; ANIMAL; DRUG DEVELOPMENT; ISOLATION AND PURIFICATION; SEA;

ANIMALS; BIOLOGICAL PRODUCTS; DRUG DISCOVERY; OCEANS AND SEAS;

EID: 79954498454     PISSN: 1934578X     EISSN: 15559475     Source Type: Journal    
DOI: None     Document Type: Review

References (141)

1. Yasuhara-Bell J, Lu Y. (2010) Marine compounds and their antiviral activities. Antiviral Research, 86, 231-240.
2. Vosmaer GCJ, Bidder GP, Vosmaer-Roëll CS. (1928) Bibliography of sponges 1551-1913. University Press, Cambridge. 234 p.
3. Thompson DW. (1885) A bibliography of protozoa, sponges, coelenterata, and worms: Including also the polyzoa, brachiopoda and tunicata, for the years 1861-1883. University Press, Cambridge. 284 p.
4. Krukenberg CFW. (1880) Küsten der Adria, experimentelle Untersuchungen. Vergleichend-Physiologische Studien, Bath II, 1-273.
5. Krukenberg CFW. (1880) Studien zu Tunis; Mentone und Palermo, experimentelle Untersuchungen. Vergleichend-Physiologische Studien, Bath III, 1-192.
6. Krukenberg CFW. (1880) Küsten der Adria, experimentelle Untersuchungen. Vergleichend-Physiologische Studien, Bath I, 1-108.
7. Krukenberg CFW. (1882) Die Floridine der Eenieren, experimentelle Untersuchungen. Vergleichend-Physiologische Studien, Bath 3, 3560-3640.
8. Krukenberg CFW. (1882) Ueber die melanotischen Verfarbungen der Uranidine, experimentelle Untersuchungen. Vergleichend-Physiologische Studien, Bath 3, 4111-4156.
9. Krukenberg CFW. (1882) Die Lipochrome der Spongien, experimentelle Untersuchungen. Vergleichend-Physiologische Studien, Bath 3, 108085-108115.
10. Dorée C. (1909) The occurrence and distribution of cholesterol and allied bodies in the animal kingdom. Biochemical Journal, 4, 72-106.
11. Henze M. (1904) Spongosterin, eine cholesterinartige Substanz aus Suberites domuncula, und seine angebliche Beziehung zum Lipochrom dieses Tieres. Hoppe-Seyler's Zeitschrift für physiologische Chemie, 41, 109-124.
12. Henze M. (1908) Über Spongosterin, das Cholesterin aus Suberites domuncula. Hoppe-Seyler's Zeitschrift für physiologische Chemie, 55, 427-432.
13. Pratt R, Daniels TC, Eiler J, Gunnison J, Kumler W, Oneto JF, Strait LA, Spoehr HA, Hardin GJ, Milner HW, Smith JH, Strain HH. (1944) Chlorellin; an antibacterial substance from Chlorella. Science, 99, 351-352.
14. Taft C. (1945) Poisonous marine animals. Texas Reports on Biology and Medicine, 10, 43-55.
15. Emerson G, Taft C. (1945) Pharmacologically active agents from the sea. Texas Reports on Biology and Medicine, 3, 302-338.
16. Pratt R, Mautner H, Gardner GM, Sha YH, Dufrenoy J. (1951) Report on antibiotic activity of seaweed extracts. Journal of the American Pharmaceutical Association, 40, 575-579.
17. Burkholder PR, Burkholder LM, Almodóvar LR. (1960) Antibiotic activity of some marine algae of Puerto Rico. Botanica Marina, 2, 149-156.
18. Bergmann W, Feeney RJ. (1951) Contributions to the study of marine products. XXXII. The nucleosides of sponges I. The Journal of Organic Chemistry, 16, 981-987.
19. Stahl E. (1956) Thin-layer chromatography; methods, influencing factors and an example of its use. Pharmazie, 11, 633-637.
20. Stahl E. (1958) Thin-layer chromatography. II. Standardization; detection; documentation and application. Chemiker Zeitung, 82, 323-329.
21. Bergmann W, Burke DC. (1955) Contributions to the study of marine products. XXXIX. The nucleosides of sponges. III. Spongothymidine and spongouridine. The Journal of Organic Chemistry, 20, 1501-1507.
22. Evans JS, Musser EA, Mengel GD, Forsblad KR, Hunter JH. (1961) Antitumor activity of 1-beta-D-arainofuranosylcytosine hydrochloride. Proceedings of the Society for Experimental Biology and Medicine, 106, 350-353.
23. Cohen SS. (1963) Sponges, cancer chemotherapy, and cellular aging. Perspectives in Biology and Medicine, 6, 215-227.
24. Horwitz JP, Chua J, Noel M. (1964) Nucleosides. V. The monomesylates of 1-(2′-deoxy-β-D-lyxofuranosyl)thymine1,2. The Journal of Organic Chemistry, 29, 2076-2078.
25. Dixon RL, Adamson RH. (1965) Antitumor activity and pharmacologic disposition of cytosine arabinoside (NSC-63878). Cancer Chemotherapy Reports. Part 1, 48, 11-16.
26. Heidelberger C. (1967) Cancer chemotherapy with purine and pyrimidine analogues. Annual Review of Pharmacology, 7, 101-124.
27. Mayer AMS. (1999) Marine pharmacology in 1998: Antitumor and cytotoxic compounds. The Pharmacologist, 41, 159-164.
28. Mayer AMS, Gustafson KR. (2003) Marine pharmacology in 2000: Antitumor and cytotoxic compounds. International Journal of Cancer, 105, 291-299. (Pubitemid 36570039)
29. Mayer AMS, Gustafson KR. (2004) Marine pharmacology in 2001-2: Antitumor and cytotoxic compounds. European Journal of Cancer, 40, 2676-2704. (Pubitemid 39574721)
30. Mayer AMS, Gustafson KR. (2006) Marine pharmacology in 2003-2004: Antitumour and cytotoxic compounds. European Journal of Cancer, 42, 2241-2270. (Pubitemid 44307627)
31. Mayer AMS, Gustafson KR. (2008) Marine pharmacology in 2005-2006: Antitumour and cytotoxic compounds. European Journal of Cancer, 44, 2357-2387.
32. Mayer AMS, Hamann M. (2004) Marine pharmacology in 2000: Marine compounds with antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiplatelet, antituberculosis, and antiviral activities; affecting the cardiovascular, immune, and nervous systems and other miscellaneous mechanisms of action. Marine Biotechnology, 6, 37-52. (Pubitemid 38390987)
33. Mayer AMS, Hamann MT. (2002) Marine pharmacology in 1999: compounds with antibacterial, anticoagulant, antifungal, anthelmintic, anti-inflammatory, antiplatelet, antiprotozoal and antiviral activities affecting the cardiovascular, endocrine, immune and nervous systems, and other miscellaneous mechanisms of action. Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology, 132, 315-339. (Pubitemid 34879836)
34. Mayer AMS, Hamann MT. (2005) Marine pharmacology in 2001-2002: Marine compounds with anthelmintic, antibacterial, anticoagulant, antidiabetic, antifungal, anti-inflammatory, antimalarial, antiplatelet, antiprotozoal, antituberculosis, and antiviral activities; affecting the cardiovascular, immune and nervous systems and other miscellaneous mechanisms of action. Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology, 140, 265-286. (Pubitemid 40804347)
35. Mayer AMS, Lehmann VKB. (2000) Marine pharmacology in 1998: Marine compounds with antibacterial, anticoagulant, antiinflammatory, anthelmintic, antiplatelet, antiprotozoal, and antiviral activities; with actions on the cardiovascular, endocrine, immune, and nervous systems; and other miscellaneous mechanisms of action. The Pharmacologist, 42, 62-69.
36. Mayer AMS, Lehmann VKB. (2001) Marine pharmacology in 1999: Antitumor and cytotoxic compounds. Anticancer Research, 21, 2489-2500. (Pubitemid 33054415)
37. Mayer AMS, Rodríguez AD, Berlinck RGS, Fusetani N. (2011) Marine pharmacology in 2007-8: Marine compounds with antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiprotozoal, antituberculosis, and antiviral activities; affecting the immune and nervous system, and other miscellaneous mechanisms of action. Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology, 153, 191-222.
38. Mayer AMS, Rodríguez AD, Berlinck RGS, Hamann MT. (2007) Marine pharmacology in 2003-4: Marine compounds with anthelmintic antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiplatelet, antiprotozoal, antituberculosis, and antiviral activities; affecting the cardiovascular, immune and nervous systems, and other miscellaneous mechanisms of action. Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology, 145, 553-581. (Pubitemid 46660746)
39. Mayer AMS, Rodríguez AD, Berlinck RGS, Hamann MT. (2009) Marine pharmacology in 2005-6: Marine compounds with anthelmintic, antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiprotozoal, antituberculosis, and antiviral activities; affecting the cardiovascular, immune and nervous systems, and other miscellaneous mechanisms of action. Biochimica et Biophysica Acta, 1790, 283-308.
40. Food and Drug Administration, FDA, (2010) Off patent oncology drugs. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3995B1-04-Off 20Patent 20Oncology 20Drugs-Addendum.htm
41. Eridani S. (1972) Cytarabine: mechanism of action and clinical application. Haematologica, 57, 341-358.
42. Frei E, Bickers JN, Hewlett JS, Lane M, Leary WV, Talley RW. (1969) Dose schedule and antitumor studies of arabinosyl cytosine (NSC 63878). Cancer Research, 29, 1325-1332.
43. Sweetman SC. (2007) Martindale: the complete drug reference. Pharmaceutical Press, London. 3322 p.
44. National Institutes of Health, NIH. (1983) Recommendations for the safe handling of parenteral antineoplastic drugs. NIH publication, Washington D.C. NIH 83-2621.
45. Jones RB, Frank R, Mass T. (1983) Safe handling of chemotherapeutic agents: a report from The Mount Sinai Medical Center. CA: A Cancer Journal for Clinicians, 33, 258-263. (Pubitemid 13007394)
46. Schimmer AD, Estey EH, Borthakur G, Carter BZ, Schiller GJ, Tallman MS, Altman JK, Karp JE, Kassis J, Hedley DW, Brandwein J, Xu W, Mak DH, Lacasse E, Jacob C, Morris SJ, Jolivet J, Andreeff M. (2009) Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. Journal of Clinical Oncology, 27, 4741-4746.
47. Yao YY, Zhu Q, Zou LF, Dou HJ, Chen YM, Tang Y, Hu JP. (2009) Clinical study on fludarabin combined with cytarabine regimen in the treatment of patients with refractory and relapsed acute myeloid leukemia. Journal of Experimental Hematology, 17, 774-776.
48. Cimino G, De Rosa S, De Stefano S. (1984) Antiviral agents from a gorgonian, Eunicella cavolini. Cellular and Molecular Life Sciences, 40, 339-340. (Pubitemid 14126927)
49. Trobe JD, Centifanto Y, Zam ZS, Varnell E, Kaufman HE. (1976) Anti-herpes activity of adenine arabinoside monophosphate. Investigative Ophthalmology, 15, 196-199.
50. Food and Drug Administration. (1978) Vidarabine approved for herpes simplex virus encephalitis. FDA Drug Bulletin, 8, 36.
51. Cohen SS. (1977) The mechanisms of lethal action of arabinosyl cytosine (araC) and arabinosyl adenine (araA). Cancer, 40, 509-518.
52. Sasadeusz JJ, Sacks SL. (1993) Systemic antivirals in herpesvirus infections. Dermatologic Clinics, 11, 171-185. (Pubitemid 23099112)
53. Olivera B, Gray W, Zeikus R, Mcintosh J, Varga J, Rivier J, De Santos V, Cruz L. (1985) Peptide neurotoxins from fish-hunting cone snails. Science, 230, 1338-1343. (Pubitemid 16105162)
54. López J. (2001) Conotoxinas. Spira, 1, 7-11.
55. Lawson E, Wallace M. (2010) Current developments in intraspinal agents for cancer and noncancer pain. Current Pain and Headache Reports, 14, 8-16.
56. Schmidtko A, Lötsch J, Freynhagen R, Geisslinger G. (2010) Ziconotide for treatment of severe chronic pain. The Lancet, 375, 1569-1577.
57. Sigel M, Wellham L, Lichter W, Dudeck L, Gargus J, Lucas L. (1969) Food-Drugs from the Sea. Youngken HW (Ed.), Marine Technology Society, Washington DC. 281-295.
58. Rinehart KL. (1990) Ecteinascidin-729, Ecteinascidin-743, Ecteinascidin-745, Ecteinascidin-759a, Ecteinascidin-759b, and Ecteinascidin-770: Potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinata. Journal of Organic Chemistry, 55, 4512-4515.
59. Wright AE, Forleo DA, Gunawardana GP, Gunasekera SP, Koehn FE, Mcconnell OJ. (1990) Antitumor tetrahydroisoquinoline alkaloids from the colonial ascidian Ecteinascidia turbinata. The Journal of Organic Chemistry, 55, 4508-4512. (Pubitemid 20274261)
60. Cuevas C, Francesch A. (2009) Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem. Natural Product Reports, 26, 322-337.
61. Corey EJ, Gin DY, Kania RS. (1996) Enantioselective total synthesis of ecteinascidin 743. Journal of the American Chemical Society, 118, 9202-9203. (Pubitemid 26342569)
62. Cuevas C, Pérez M, Martín MJ, Chicharro JL, Fernández-Rivas C, Flores M, Francesch A, Gallego P, Zarzuelo M, De La Calle F, García J, Polanco C, Rodríguez I, Manzanares I. (2000) Synthesis of ecteinascidin ET-743 and phthalascidin Pt-650 from cyanosafracin B. Organic Letters, 2, 2545-2548.
63. [No authors listed]. (2006) Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766. Drugs in R&D, 7, 317-328.
64. Aune GJ, Furuta T, Pommier Y. (2002) Ecteinascidin 743: a novel anticancer drug with a unique mechanism of action. Anti-Cancer Drugs, 13, 545-555. (Pubitemid 34816449)
65. Burgoyne DL, Andersen RJ, Allen TM. (1992) Contignasterol, a highly oxygenated steroid with the unnatural 14-beta configuration from the marine sponge Petrosia contignata Thiele, 1899. The Journal of Organic Chemistry, 57, 525-528.
66. Yang L, Andersen RJ. (2002) Absolute configuration of the antiinflamatory sponge natural product contignasterol. Journal of Natural Products, 65, 1924-1926. (Pubitemid 36055450)
67. Takei M, Burgoyne DL, Andersen RJ. (1994) Effect of contignasterol on histamine release induced by anti-immunoglobuline from rat peritoneal mast cells. Journal of Pharmaceutical Sciences, 83, 1234-1235. (Pubitemid 24282325)
68. Bramley AM, Langlands JM, Jones AK, Burgoyne DL, Li Y, Andersen RJ, Salari H. (1995) Effects of IZP-94005 (contignasterol) on antigen-induced bronchial responsiveness in ovalbumin-sensitized guinea-pigs. British Journal of Pharmacology, 115, 1433-1438.
69. Shen Y, Burgoyne DL. (2002) Efficient synthesis of IPL576,092: A novel anti-asthma agent. The Journal of Organic Chemistry, 67, 3908-3910. (Pubitemid 34564007)
70. Leonard P, Sur S. (2002) Asthma: future directions. Medical Clinics of North America, 86, 1131-1156. (Pubitemid 35247157)
71. Gross H, König G. (2006) Terpenoids from marine organisms: Unique structures and their pharmacological potential. Phytochemistry Reviews, 5, 115-141. (Pubitemid 44114867)
72. Langlands J, Laforce C. (2006) The effect of IPL512,602 in patients with mild-moderate persistent asthma (NEAT study). Proceedings of the American Thoracic Society, 3, 80 (Abstr Suppl).
73. Rinehart KL, Gloer JB, Cook JC, Mizsak SA, Scahill TA. (1981) Structures of the didemnins, antiviral and cytotoxic depsipeptides from a Caribbean tunicate. Journal of the American Chemical Society, 103, 1857-1859. (Pubitemid 11075621)
74. Rinehart K, Jr, Gloer J, Hughes R, Jr, Renis H, Mcgovren J, Swynenberg E, Stringfellow D, Kuentzel S, Li L. (1981) Didemnins: antiviral and antitumor depsipeptides from a Caribbean tunicate. Science, 212, 933-935.
75. Hossain MB, Van Der Helm D, Antel J, Sheldrick GM, Sanduja SK, Weinheimer AJ. (1988) Crystal and molecular structure of didemnin B, an antiviral and cytotoxic depsipeptide. Proceedings of the National Academy of Sciences of the United States of America, 85, 4118-4122.
76. Crews CM, Collins JL, Lane WS, Snapper ML, Schreiber SL. (1994) GTP-dependent binding of the antiproliferative agent didemnin to elongation factor 1 alpha. Journal of Biological Chemistry, 269, 15411-15414. (Pubitemid 24202118)
77. Meng L, Sin N, Crews CM. (1998) The antiproliferative agent didemnin B uncompetitively inhibits palmitoyl protein thioesterase. Biochemistry, 37, 10488-10492. (Pubitemid 28357572)
78. Vera MD, Joullié MM. (2002) Natural products as probes of cell biology: 20 years of didemnin research. Medicinal Research Reviews, 22, 102-145. (Pubitemid 34160582)
79. Kucuk O, Young ML, Habermann TM, Wolf BC, Jimeno J, Cassileth PA. (2000) Phase II trial of didemnin B in previously treated non-Hodgkin's lymphoma : An Eastern Cooperative Oncology Group (ECOG) study. American Journal of Clinical Oncology, 23, 273-277. (Pubitemid 32428033)
80. Rinehart KL, Lithgow-Bertelloni A, (1990) Dehydrodidemnin B. US Patent RE39887. 23p.
81. Jimeno J. (2002) A clinical armamentarium of marine-derived anti-cancer compounds. Anti-Cancer Drugs, Suppl 1, 15-19.
82. Jimeno J, López-Martín JA, Ruiz-Casado A, Izquierdo MA, Scheuer PJ, Rinehart K. (2004) Progress in the clinical development of new marine-derived anticancer compounds. Anti-Cancer Drugs, 15, 321-329. (Pubitemid 38526755)
83. Broggini M, Marchini SV, Galliera E, Borsotti P, Taraboletti G, Erba E, Sironi M, Jimeno J, Faircloth GT, Giavazzi R, Dincalci M. (2003) Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4. Leukemia, 17, 52-59. (Pubitemid 36175888)
84. Muñoz-Alonso MJ, González-Santiago L, Martínez T, Losada A, Galmarini CM, Muñoz A. (2009) The mechanism of action of plitidepsin. Current Opinion in Investigational Drugs, 10, 536-542.
85. Biscardi M, Caporale R, Balestri F, Gavazzi S, Jimeno J, Grossi A. (2005) VEGF inhibition and cytotoxic effect of aplidin in leukemia cell lines and cells from acute myeloid leukemia. Annals of Oncology, 16, 1667-1674. (Pubitemid 41510142)
86. Morton CL, Houghton PJ, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups C, Smith MA. (2009) Initial testing of aplidin by the pediatric pre-clinical testing program. Pediatric Blood & Cancer, 53, 509-512.
87. Pharmamar (2010) Aplidin. http://www.pharmamar.com/aplidin-spanish.aspx
88. Le Tourneau C, Faivre S, Ciruelos E, Domínguez MJ, López-Martín JA, Izquierdo MA, Jimeno J, Raymond E. (2010) Reports of clinical benefit of plitidepsin (aplidine), a new marine-derived anticancer agent, in patients with advanced medullary thyroid carcinoma. American Journal of Clinical Oncology, 33, 132-136.
89. Schöffski P, Guillem V, Garcia M, Rivera F, Tabernero J, Cullell M, Lopez-Martin JA, Pollard P, Dumez H, Garcia Del Muro X, Paz-Ares L. (2009) Phase II randomized study of plitidepsin (aplidin), alone or in association with L-carnitine, in patients with unresectable advanced renal cell carcinoma. Marine Drugs, 7, 57-70.
90. Pettit GR, Ode RH, Herald CL, Von Dreele RB, Michel C. (1976) Antineoplastic agents. 46. The isolation and structure of dolatriol. Journal of the American Chemical Society, 98, 4677-4678.
91. Pettit GR, Kamano Y, Fujii Y, Herald CL, Inoue M, Brown P, Gust D, Kitahara K, Schmidt JM, Doubek DL, Michael C. (1981) Marine animal biosynthetic constituents for cancer chemotherapy. Journal of Natural Products, 44, 482-485. (Pubitemid 12230441)
92. Harrigan GG, Luesch H, Yoshida WY, Moore RE, Nagle DG, Paul VJ, Mooberry SL, Corbett TH, Valeriote FA. (1998) Symplostatin 1: A dolastatin 10 analogue from the marine cyanobacterium Symploca hydnoides. Journal of Natural Products, 61, 1075-1077. (Pubitemid 28464730)
93. Pettit GR, Kamano Y, Herald CL, Tuinman AA, Boettner FE, Kizu H, Schmidt JM, Baczynskyj L, Tomer KB, Bontems RJ. (1987) The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin 10. Journal of the American Chemical Society, 109, 6883-6885. (Pubitemid 18036607)
94. Bai RL, Pettit GR, Hamel E. (1990) Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and Vinca alkaloid sites. Journal of Biological Chemistry, 265, 17141-17149.
95. Jordan A, Hadfield JA, Lawrence NJ, Mcgown AT. (1998) Tubulin as a target for anticancer drugs: Agents which interact with the mitotic spindle. Medicinal Research Reviews, 18, 259-296. (Pubitemid 28346389)
96. Pettit GR. (1989) The absolute-configuration and synthesis of natural (-)-Dolastatin-10. Journal of the American Chemical Society, 111, 5463-5465.
97. Madden T, Tran HT, Beck D, Huie R, Newman RA, Pusztai L, Wright JJ, Abbruzzese JL. (2000) Novel marine-derived anticancer agents: A phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors. Clinical Cancer Research, 6, 1293-1301. (Pubitemid 30226211)
98. Vaishampayan U, Glode M, Du W, Kraft A, Hudes G, Wright J, Hussain M. (2000) Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma. Clinical Cancer Research, 6, 4205-4208.
99. Margolin K, Longmate J, Synold TW, Gandara DR, Weber J, Gonzalez R, Johansen MJ, Newman R, Baratta T, Doroshow JH. (2001) Dolastatin-10 in metastatic melanoma: A phase II and pharmokinetic trial of the California cancer consortium. Investigational New Drugs, 19, 335-340. (Pubitemid 32785281)
100. Kobayashi M, Natsume T, Tamaoki S, Watanabe JI, Asano H, Mikami T, Miyasaka K, Miyazaki K, Gondo M, Sakakibara K, Tsukagoshi S. (1997) Antitumor activity of TZT-1027, a novel doiastatin 10 derivative. Cancer Science, 88, 316-327. (Pubitemid 27170493)
101. Patel S, Keohan ML, Saif MW, Rushing D, Baez L, Feit K, Dejager R, Anderson S. (2006) Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy. Cancer, 107, 2881-2887. (Pubitemid 44937043)
102. Riely GJ, Gadgeel S, Rothman I, Saidman B, Sabbath K, Feit K, Kris MG, Rizvi NA. (2007) A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy. Lung Cancer, 55, 181-185. (Pubitemid 46074222)
103. Yamamoto N, Andoh M, Kawahara M, Fukuoka M, Niitani H. (2009) Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, given weekly to advanced solid tumor patients for 3 weeks. Cancer Science, 100, 316-321.
104. Pettit GR, Kamano Y, Dufresne C, Cerny RL, Herald CL, Schmidt JM. (1989) Isolation and structure of the cytostatic linear depsipeptide dolastatin 15. The Journal of Organic Chemistry, 54, 6005-6006. (Pubitemid 20063834)
105. Cruz-Monserrate Z, Mullaney JT, Harran PG, Pettit GR, Hamel E. (2003) Dolastatin 15 binds in the vinca domain of tubulin as demonstrated by Hummel-Dreyer chromatography. European Journal of Biochemistry, 270, 3822-3828. (Pubitemid 37123254)
106. Smyth J, Boneterre ME, Schellens J, Calvert H, Greim G, Wanders J, Hanauske A. (2001) Activity of the dolastatin analogue, LU103793, in malignant melanoma. Annals of Oncology, 12, 509-511. (Pubitemid 32472107)
107. Newman DJ, Cragg GM. (2004) Marine natural products and related compounds in clinical and advanced preclinical trials. Journal of Natural Products, 67, 1216-1238. (Pubitemid 39145623)
108. Mita AC, Hammond LA, Bonate PL, Weiss G, Mccreery H, Syed S, Garrison M, Chu QSC, Debono JS, Jones CB, Weitman S, Rowinsky EK. (2006) Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors. Clinical Cancer Research, 12, 5207-5215. (Pubitemid 44453350)
109. Ray A, Okouneva T, Manna T, Miller HP, Schmid S, Arthaud L, Luduena R, Jordan MA, Wilson L. (2007) Mechanism of action of the microtubule-targeted antimitotic depsipeptide tasidotin (formerly ILX651) and its major metabolite tasidotin C-carboxylate. Cancer Research, 67, 3767-3776. (Pubitemid 46762163)
110. Kilburn L, Bonate P, Blaney S, Mcguffey L, Nuchtern J, Dauser R, Thompson P, Gibson B, Berg S. (2009) Plasma and cerebrospinal fluid pharmacokinetics of tasidotin (ILX-651) and its metabolites in non-human primates. Cancer Chemotherapy and Pharmacology, 64, 335-340.
111. Mcdermott DF, Hersh E, Weber J, Stephenson J, Cunningham CC, Ebbinghaus S, Thompson J, O'day S, Weitman S, Hammond L. (2005) ILX651 administered daily for five days every 3 weeks (qdx5dq3w) in patients (pts) with inoperable locally advanced or metastatic melanoma: Phase II experience. Journal of Clinical Oncology, 23, 7556 (Abstr Suppl).
112. Hirata Y, Uemura D. (1986) Halichondrins - antitumor polyether macrolides from a marine sponge. Pure and Applied Chemistry, 58, 701-710. (Pubitemid 16557441)
113. Aicher TD, Buszek KR, Fang FG, Forsyth CJ, Jung SH, Kishi Y, Matelich MC, Scola PM, Spero DM, Yoon SK. (1992) Total synthesis of halichondrin B and norhalichondrin B. Journal of the American Chemical Society, 114, 3162-3164.
114. Bai RL, Paull KD, Herald CL, Malspeis L, Pettit GR, Hamel E. (1991) Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. Journal of Biological Chemistry, 266, 15882-15889. (Pubitemid 21907740)
115. Fodstad O, Breistøl K, Pettit GR, Shoemaker RH, Boyd MR. (1996) Comparative antitumor activities of halichondrins and vinblastine against human tumor xenografts. Journal of Experimental Therapeutics and Oncology, 1, 119-125.
116. Wang Y, Habgood GJ, Christ WJ, Kishi Y, Littlefield BA, Yu MJ. (2000) Structure-activity relationships of Halichondrin B analogues: modifications at C30-C38. Bioorganic & Medicinal Chemistry Letters, 10, 1029-1032. (Pubitemid 30406459)
117. Towle MJ, Salvato KA, Budrow J, Wels BF, Kuznetsov G, Aalfs KK, Welsh S, Zheng W, Seletsky BM, Palme MH, Habgood GJ, Singer LA, Dipietro LV, Wang Y, Chen JJ, Quincy DA, Davis A, Yoshimatsu K, Kishi Y, Yu MJ, Littlefield BA. (2001) In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Research, 61, 1013-1021. (Pubitemid 32174419)
118. Jackson KL, Henderson JA, Phillips AJ. (2009) The halichondrins and E7389. Chemical Reviews, 109, 3044-3079.
119. Hamann MT, Scheuer PJ. (1993) Kahalalide F: a bioactive depsipeptide from the sacoglossan mollusk Elysia rufescens and the green alga Bryopsis sp. Journal of the American Chemical Society, 115, 5825-5826. (Pubitemid 23251093)
120. Sewell JM, Mayer I, Langdon SP, Smyth JF, Jodrell DI, Guichard SM. (2005) The mechanism of action of Kahalalide F: Variable cell permeability in human hepatoma cell lines. European Journal of Cancer, 41, 1637-1644. (Pubitemid 40981847)
121. Pardo B, Paz-Ares L, Tabernero J, Ciruelos E, García M, Salazar R, López A, Blanco M, Nieto A, Jimeno J, Izquierdo MA, Trigo JM. (2008) Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors. Clinical Cancer Research, 14, 1116-1123. (Pubitemid 351302559)
122. Salvador MA, Enrique E, Jordi R, Juan José López L, José Luis M, Lorenzo Alonso C, Arrate P, Adnan T, Luis PA. (2009) Phase II study of weekly Kahalalide F in patients with advanced malignant melanoma. European Journal of Cancer, 45, 732-735.
123. Zeltia G, (2010) Informe a 30 de junio de 2010. http://www.zeltia.com/ media/docs/sycwigvc.pdf
124. Provencio M, Sánchez A, Gasent J, Gómez P, Rosell R. (2009) Cancer treatments: Can we find treasures at the bottom of the sea? Clinical Lung Cancer, 10, 295-300.
125. Pettit GR, Herald CL, Doubek DL, Herald DL, Arnold E, Clardy J. (1982) Isolation and structure of bryostatin 1. Journal of the American Chemical Society, 104, 6846-6848. (Pubitemid 13182924)
126. Schaufelberger DE, Koleck MP, Beutler JA, Vatakis AM, Alvarado AB, Andrews P, Marzo LV, Muschik GM, Roach J, Ross JT, Lebherz WB, Reeves MP, Eberwein RM, Rodgers LL, Testerman RP, Snader KM, Forenza S. (1991) The large-scale isolation of bryostatin 1 from Bugula neritina following current good manufacturing practices. Journal of Natural Products, 54, 1265-1270.
127. Mendola D. (2003) Aquaculture of three phyla of marine invertebrates to yield bioactive metabolites: process developments and economics. Biomolecular Engineering, 20, 441-458.
128. Wender PA, Cribbs CM, Koehler KF, Sharkey NA, Herald CL, Kamano Y, Pettit GR, Blumberg PM. (1988) Modeling of the bryostatins to the phorbol ester pharmacophore on protein kinase C. Proceedings of the National Academy of Sciences of the United States of America, 85, 7197-7201.
129. Mutter R, Wills M. (2000) Chemistry and clinical biology of the bryostatins. Bioorganic & Medicinal Chemistry, 8, 1841-1860. (Pubitemid 30612475)
130. Winegarden JD, Mauer AM, Gajewski TF, Hoffman PC, Krauss S, Rudin CM, Vokes EE. (2003) A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer. Lung Cancer, 39, 191-196. (Pubitemid 36173620)
131. Molinski TF, Dalisay DS, Lievens SL, Saludes JP. (2009) Drug development from marine natural products. Nature Reviews. Drug Discovery, 8, 69-85.
132. Khan TK, Nelson TJ, Verma VA, Wender PA, Alkon DL. (2009) A cellular model of Alzheimer's disease therapeutic efficacy: PKC activation reverses Aβ-induced biomarker abnormality on cultured fibroblasts. Neurobiology of Disease, 34, 332-339.
133. Ayral-Kaloustian S, Zask A. (2005) Taltobulin. Drugs of the Future, 30, 254-260.
134. Hadaschik BA, Ettinger S, Sowery RD, Zoubeidi A, Andersen RJ, Roberge M, Gleave ME. (2008) Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin. International Journal of Cancer, 122, 2368-2376. (Pubitemid 351542344)
135. Niu C, Ho DM, Zask A, Ayral-Kaloustian S. (2010) Absolute configurations of tubulin inhibitors taltobulin (HTI-286) and HTI- 042 characterized by X-ray diffraction analysis and NMR studies. Bioorganic & Medicinal Chemistry Letters, 20, 1535-1538.
136. D'agostino G, Del Campo J, Mellado B, Izquierdo M, Minarik T, Cirri L, Marini L, Perez-Gracia J, Scambia G. (2006) A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer. International Journal of Gynecological Cancer, 16, 71-76.
137. Freedman R, Olincy A, Buchanan RW, Harris JG, Gold JM, Johnson L, Allensworth D, Guzman-Bonilla A, Clement B, Ball MP, Kutnick J, Pender V, Martin LF, Stevens KE, Wagner BD, Zerbe GO, Soti F, Kem WR. (2008) Initial phase 2 trial of a nicotinic agonist in schizophrenia. American Journal of Psychiatry, 165, 1040-1047.
138. Stevens KE, Cornejo B, Adams CE, Zheng L, Yonchek J, Hoffman KL, Christians U, Kem WR. (2010) Continuous administration of a selective α-7 nicotinic partial agonist, DMXBA, improves sensory inhibition without causing tachyphylaxis or receptor upregulation in DBA/2 mice. Brain Research, 1352, 140-146.
139. Leal JFM, García-Hernández V, Moneo V, Domingo A, Bueren-Calabuig JA, Negri A, Gago F, Guillén-Navarro MJ, Avilés P, Cuevas C, García-Fernández LF, Galmarini CM. (2009) Molecular pharmacology and antitumor activity of Zalypsis® in several human cancer cell lines. Biochemical Pharmacology, 78, 162-170.
140. Singh AV, Palladino MA, Lloyd GK, Potts BC, Chauhan D, Anderson KC. (2010) Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model. British Journal of Haematology, 149, 550-559.
141. Kuznetsov G, Tendyke K, Towle MJ, Cheng H, Liu J, Marsh JP, Schiller SER, Spyvee MR, Yang H, Seletsky BM, Shaffer CJ, Marceau V, Yao Y, Suh EM, Campagna S, Fang FG, Kowalczyk JJ, Littlefield BA. (2009) Tubulin-based antimitotic mechanism of E7974, a novel analogue of the marine sponge natural product hemiasterlin. Molecular Cancer Therapeutics, 8, 2852-2860.